All In Biotech

Drug Trial Radar · NCT06564467

A Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of JMT202

A Phase І, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of JMT202 Injection in Chinese Healthy Participants

Last checked: Nov 19, 2026Latest source record: Aug 22, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

54

Planned (sponsor's estimate)

Start

Jul 23, 2024

Primary completion

Jan 10, 2025

Study completion Jul 10, 2025

Sponsor

Lead sponsor
Shanghai JMT-Bio Inc.Industry
Sponsor type
Industry
First posted
Aug 21, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 60 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a randomized, double-blind, placebo-controlled, single ascending dose (SAD) study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneously Administered JMT202 in Healthy Participants.

Conditions

  • Healthy Subjects

Interventions

  • JMT202Drug

    subcutaneous injection

  • PlacrboDrug

    subcutaneous injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The Number of adverse events (AEs) electrocardiogramsTime frame: Pre-dose and multiple timepoints no less than 50 days
  2. Number of participants with clinically significant change from baseline in vital signsTime frame: Pre-dose and multiple timepoints no less than 50 days
  3. Number of participants with clinically significant change from baseline in electrocardiogram (ECG) findingsTime frame: Pre-dose and multiple timepoints no less than 50 days
  4. Number of participants with clinically significant abnormalities in physical examinationTime frame: Pre-dose and multiple timepoints no less than 50 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Peking University First Hospital

    Beijin, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.